Clincosm LogoSign in Get a demo

Implementation of a Pharmacist-Based, Post-Chemotherapy Follow-up Clinic

Sponsor
Cedars-Sinai Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05965206
Collaborator
(none)
40
Enrollment
1
Location
24.4
Anticipated Duration (Months)
1.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the impact of pharmacists on reducing chemotherapy-related side effects by providing education before and after patients receive intravenous chemotherapy at one of Cedars-Sinai outpatient infusion centers.

Participants will be interviewed via telephone within 7 business days after receiving intravenous chemotherapy from the outpatient cancer center infusion clinic.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Follow-up phone interview

Detailed Description

The study involves participation at a single timepoint only.

Participants who consented to participate and are considered eligible will be interviewed by a pharmacist via phone at approximately 7 business days after receiving intravenous chemotherapy infusion. Phone call will be made between the hours of 9am - 6pm on Monday - Saturday. Calls are anticipated to last between 15 to 20 minutes. Participants will be asked if they have experienced any adverse events since the infusion, whether or not they have had any barriers taking supportive care medications, and if the patient understands how to manage potential adverse events. If applicable, participants will be provided further education on optimizing adverse events, guided on proper medication administration times, and will be provided with non-pharmacological clinical pearls to minimize chemotherapy-related side effects and optimize supportive care management.

If unable to reach the participant or caregiver after three attempts, the participant will be considered ineligible. Participants can decline participation at any time during the phone call.

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Implementation of a Pharmacist-Based, Post-Chemotherapy Follow-up Clinic
Actual Study Start Date :
Jul 20, 2023
Anticipated Primary Completion Date :
Jul 31, 2024
Anticipated Study Completion Date :
Jul 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Intervention group

Participants receive a follow-up phone call from a pharmacist approximately 7 business days after receiving intravenous chemotherapy infusion

Behavioral: Follow-up phone interview
Follow-up phone interview within 7 business days after receiving intravenous chemotherapy
Other Names:
  • Follow-up call

    		•
    Control group

    Participants do not receive a follow-up phone call from a pharmacist after receiving intravenous chemotherapy infusion

    Outcome Measures

    Primary Outcome Measures

    1. Hospital admission related to chemotherapy within 30-day post treatment [30 days after receiving the first intravenous chemotherapy]

      Number of hospital admission related to chemotherapy

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • At least 18 years old

    • Diagnosed with cancer and is receiving treatment with intravenous chemotherapy

    • Treatment initiated at Cedars-Sinai Cancer Samuel Oschin Cancer Center (SOCC) or Cedars-Sinai Cancer Beverly Hills (CSCBH)

    • English-speaking or lives with English-speaking person

    • Access to a working phone

    Exclusion Criteria:

    • Received follow-up calls through other specialty pharmacy program

    • History of infusion related reactions

    • Declined participation on follow-up interview

    • Age less than 18 years old

    • Non-English speaking

    • Electronic health record flagged for research opt out

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cedars-Sinai Medical Center Los Angeles California United States 90048

    Sponsors and Collaborators

    • Cedars-Sinai Medical Center

    Investigators

    • Principal Investigator: Suwicha Limvorasak, PharmD, Cedars-Sinai Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Suwicha Limvorasak, PharmD, Cedars-Sinai Medical Center
    ClinicalTrials.gov Identifier:
    NCT05965206
    Other Study ID Numbers:
    • Study00002683
    First Posted:
    Jul 28, 2023
    Last Update Posted:
    Jul 28, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Suwicha Limvorasak, PharmD, Cedars-Sinai Medical Center
    Pharmacist
    Follow up clinic

    Study Results

    No Results Posted as of Jul 28, 2023